BioSpace News Archive

Mnemo Therapeutics, a biotechnology company developing next-generation T cell therapies, announced the appointment of Robert LaCaze as the company’s new chief executive officer effective May 1.

Nicox SA, an international ophthalmology company, provides an update on the approvals and launches of VYZULTA, 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc.

The past year was very exciting for BioInvent. Two of our clinical trials provided highly encouraging results in 2021 at the same time as we expanded our pipeline of clinical programs with the initiation of two additional programs and the submission of one clinical trial application, more than doubling the portfolio.

Faron Pharmaceuticals Ltd announces updated survival data from Phase I/II MATINS study investigating the safety and efficacy of bexmarilimab.

Vicore Pharma Holding AB, a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor, announces advancing its first new chemical entity from the VP03 program to a first in human phase 1 trial.

Complement Therapeutics Ltd, a preclinical stage University of Manchester spinout, announced the completion of its EUR 5 million seed financing round from BioGeneration Ventures and Forbion, two leading European venture capital firms.

Sanofi and GSK announce that they intend to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets.

Kodiak Sciences Inc. announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular age-related macular degeneration.

Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets.